La startup SocialDiabetes, membre de CATALONIA.HEALTH, anuncia una aliança estratègica amb l’empresa Listen.Doctor i la multinacional tecnològica Babel per introduir solucions avançades en intel·ligència artificial i tecnologies de monitoratge que estan transformant l’atenció sanitària
The technology centre Eurecat, a member of CATALONIA.HEALTH, will apply the new single-cell genomic technology to evaluate the health impact of a diet based on alternative protein sources and characterize cells from cultivated meat, thus moving towards precision nutrition
The venture capital company Inveready has acquired Enantia, a company specialized in contract research (CRO). Both companies are members of CATALONIA.HEALTH. The acquisition has been done through INVACO, one of the companies controlled by the venture capital fund Inveready Biotech IV.
The pharmaceutical company Bionure and the Hospital del Mar Research Institute, both members of CATALONIA.HEALTH, establish a strategic collaboration to transform the treatment landscape of neurodegenerative diseases, such as Amyotrophic Lateral Sclerosis (ALS) or Epilepsy, with RNA therapies.
After several years participating laterally at the Mobile World Congress (MWC), the largest and most influential event on connectivity worldwide, and at 4YFN, the parallel event to the MWC of reference for the international entrepreneurial ecosystem, CATALONIA.HEALTH lands at the 2025 edition with a stand that will allow to present, in an interactive way, medical technologies from 8 companies' members.
The venture capital company Asabys Partners, a member of CATALONIA.HEALTH, co-leads a $50 million funding round for the biotechnology company Quibim.
The venture capital company Ship2B Ventures, a member of CATALONIA.HEALTH, created a financing round with the European consortium formed with LUMO Labs through its BSocial Impact Fund to obtain funding for the technology startup Sycai Medical.
The biotech company Aptadel Therapeutics, a member of CATALONIA.HEALTH, has announced a partnership with the Little Warrior Foundation. The foundation, based in the United States, will provide $500,000 in funding for its therapeutic programme against Ewing's sarcoma, specifically for the pre-clinical phases.
The biopharmaceutical company HIPRA, a member of CATALONIA.HEALTH, launches HIPRA Biotech Services, its new unit aimed at offering development and manufacturing services of biological products to companies in the biotechnology and pharmaceutical sectors. HIPRA Biotech Services covers the entire life cycle of the product, from the initial phases of research and development to production on a commercial scale.
Triana, a company specialised in packaging and manufacturing of plastic containers for the pharmaceutical industry and a member of CATALONIA.HEALTH, announces its participation in two key events in the packaging sector, Pharmapack and Paris Packaging Week 2025, which will take place in the city of Paris during the month of January.
The pharmaceutical company Almirall, a member of CATALONIA.HEALTH, announced at the JPMorgan HealthCare 2025 Conference, an update of its strategy and business perspectives.
Medical technology company Vitalera, a member of CATALONIA.HEALTH, achieved a significant milestone by successfully completing the rigorous re-classification process to MDR Class IIa certification.
The venture capital company Invivo Partners, a member of CATALONIA.HEALTH, announced the closing of a €20 million Series A financing round for the biotechnology company Neumirna Therapeutics.
The call for the eleventh edition of the CATALONIA.HEALTH Award is now open. Previously known as Bioèxit Award, the recognition joins the change of the association's brand and adapts the name to include all sector actors.
From CATALONIA.HEALTH we wish you a happy 2025, very especially to the more than 240 members, as well as to the companies and collaborating organisations and health professionals who have accompanied us during this year. We hope you continue with us in 2025!
Durant el 2016 el grup quimicofarmacèutic Esteve va facturar 915 milions d’euros, xifra que suposa un augment del 5% respecte l’any anterior, segons informa La Vanguardia. La companyia té previst destinar 150 milions d'euros fins al 2019 per ampliar la capacitat productiva de les seves plantes. Actualment, Esteve compta amb cinc plantes productives a Banyeres del Penedès (Tarragona), Martorelles (Barcelona), Celrà (Girona), Jiutepec (Mèxic) i Shaoxing (Xina).
Segons el conseller delegat, Albert Esteve, "el 2016 va ser un any positiu perquè els negocis del grup van assolir les expectatives marcades". Cal destacar que el 63% de la facturació correspon al negoci internacional, una de les apostes de creixement de la companyia que considera el mercat espanyol "molt important, però amb creixement limitat".
El 2017 el grup preveu facturar 1.050 milions d'euros, que suposaria un 15% més, i té previst seguir un pla triennal per arribar a facturar entre 1.300 i 1.500 milions d'euros el 2019. Actualment hi treballen més de 2.000 persones a tot el món.
Foto: D'esquerra a dreta, Albert Esteve, conseller delegat, i Joan Esteve, president de la farmacèutica - © Esteve.
Configuració de cookies
Recopilem i processem la vostra informació personal amb les següents finalitats: Analítiques, Seguretat & Màrqueting.
Comentaris